Therapeutic Effect of Extended Uvulopalatal Flap Surgery in Patients With Obstructive Sleep Apnea

Article information

Sleep Med Res. 2022;13(2):94-102
Publication date (electronic) : 2022 September 26
doi : https://doi.org/10.17241/smr.2022.01298
1Department of Otorhinolaryngology-Head and Neck Surgery, Research Institute for Medical Science, Chungnam National University College of Medicine, Daejeon, Korea
2Department of Medical Science, Chungnam National University College of Medicine, Daejeon, Korea
Corresponding Author Yong Min Kim, MD, PhD Department of Otorhinolaryngology-Head and Neck Surgery, Research Institute for Medical Science, Chungnam National University College of Medicine, 266 Munhwa-ro, Jung-gu, Daejeon 35015, Korea Tel +82-42-280-7696 Fax +82-42-253-4059 E-mail entkym@cnu.ac.kr
Received 2022 May 27; Revised 2022 June 10; Accepted 2022 July 18.

Abstract

Background and Objective

Although numerous studies have reported surgical results of uvulopalatopharyngoplasty, efficacies of extended uvulopalatal flap (EUPF) surgery have only been reported in a few studies. Thus, the aim of this study was to evaluate the success rate of EUPF and investigate the advantage and practicality of this surgery.

Methods

Medical records of patients who underwent EUPF surgery were retrospectively analyzed. Through medical record analysis, demographic information was confirmed. Postoperative polysomnography (PSG) results were divided into a surgical ‘success’ group and a ‘failure’ group. Patients’ PSG results, questionnaires, and cephalometry were comparatively analyzed.

Results

All sleep parameters of PSG except rapid eye movement latency and hypopnea index were significantly improved after surgery. Ten patients were in the success group (success rate, 33.3%) and 20 patients were in the failure group. Among preoperative PSG parameters, apnea-hypopnea index, apnea index, and number of awakenings showed significant differences between the two groups. However, there were no significant differences in results of cephalometry or Friedman stage between the two groups.

Conclusions

The EUPF surgery can change sleep factors and improve subjective symptoms in obstructive sleep apnea patients. It could be considered as one of the treatment options for patients with surgical indications, although its success rate was only 33.3%.

INTRODUCTION

The importance of treatment for adult obstructive sleep apnea (OSA) has recently been emphasized because OSA has various side effects such as cardiovascular diseases, daytime sleepiness, and metabolic disorders [1,2]. In order to diagnose OSA, a physical examination is performed along with patient’s history taking and questionnaire, which are subjective evaluation methods. In addition, a flexible laryngoscopy or drug-induced sleep endoscopy (DISE) can be used to confirm the site of upper airway obstruction [3,4]. Although cephalometric analysis can be used for objective evaluation, the most important diagnostic method is polysomnography (PSG) [1,5]. Treatment modalities for adult OSA can be mainly divided into surgical and non-surgical treatments such as drugs, oral appliances, and continuous positive airway pressure (CPAP) [1,6-9]. The treatment method for a patient is carefully decided by considering the upper airway obstruction site, the severity of the disease, the presence of comorbidities, the compliance with CPAP use, and the patient’s social requirements [10-15]. As the primary goal of surgical treatment is to widen the area of the upper airway that causes apnea during sleep, the operation range should be determined according to the extent of obstruction area and the obstruction site.

When the oropharynx causes OSA, the uvulopalatopharyngoplasty (UPPP) devised and published by Fujita et al. [16] in 1981 is often used. After performing bilateral tonsillectomy and making an incision along the glossopalatal arch, UPPP widens the palate by dissecting submucosal tissues of the soft palate together with the uvula. It pulls the posterior pillar of the tonsil forward and causes it to be fixed on the upper side. However, UPPP can cause complications such as postoperative edema, pain, and velopharyngeal incompetence (VPI) due to deformation of the soft palate [17-19]. To alleviate these side effects, Powell et al. [20] announced the uvulopalatal flap in 1996 and Li et al. [21] introduced the extended uvulopalatal flap (EUPF) in 2003. Although many studies have been conducted and published on results of surgery after UPPP, only a few studies on efficacies of EUPF surgery both in South Korea and abroad have been reported. Thus, the aim of this study was to evaluate the success rate of EUPF and investigate the advantage and practicality of this surgery.

METHODS

Participants

From January 1, 2018 to December 31, 2021, medical records of patients who underwent EUPF surgery at the Department of Otorhinolaryngology-Head and Neck Surgery, Chungnam National University Hospital (CNUH) with PSG before and after surgery were retrospectively analyzed. Of a total of 71 patients, 30 completed preoperative and postoperative PSG. Through medical record review, demographic information including patient’s sex and age, type of surgery, body mass index (BMI, kg/m2), follow-up period, PSG results, questionnaires, comorbidities, and complications were obtained. Friedman stage was measured by confirming the patient’s tonsil size as well as Friedman palate position through physical examination [22]. This study was conducted after obtaining approval from the Institutional Review Board (IRB) of CNUH (IRB File No. 2022-06-004).

Surgical Procedure

Extended uvulopalatal flap

All patients were operated by the same surgeon under general anesthesia. After performing bilateral tonsillectomy, incisions were added to superior-laterally from the anterior pillar to the upper pole of tonsillar fossa. After designing the uvulopalatal flap with a pen, the mucosa and submucosal adipose tissue were dissected and removed while preserving the muscle layer using a cold knife and an electrosurgical pencil (Electrosurgical Pencils with EdgeTM Coated Electrodes; Medtronic, Minneapolis, MN, USA). If the uvula was redundant or elongated, the uvular was partially resected at this stage. The uvulopalatal flap was lifted in the soft palate direction and sutured using 3-0 coated VICRYL® (Ethicon Inc., Cornelia, GA, USA) and Monosyn® (B.Braun, Barcelona, Spain). The anterior pillar, superior constrictor muscle, and posterior pillar were sutured together 2–3 times using VICRYL® (Fig. 1).

Fig. 1.

Extended uvulopalatal flap surgery. A: Soft palate and uvula before surgery. B: After bilateral tonsillectomy. C: A submucosal flap of the soft palate was removed by extending the incision on the upper pole of the tonsils on both sides. D: The uvula is folded over the soft palate and fixed with sutures.

Septoturbinoplasty and tongue base radiofrequency volume reduction

All patients underwent a physical examination including a Müller maneuver before surgery. An objective evaluation was performed with acoustic rhinometry and rhinomanometry for symptoms such as nasal obstruction. A single skilled surgeon performed all operations. Osteomeatal unit computed tomography (OMU CT) was taken as needed. Patients with chronic rhinosinusitis (CRS) or chronic rhinosinusitis with nasal polyp underwent endoscopic sinus surgery at the same time. In addition, when inferior turbinate hypertrophy and tongue base obstruction were observed, radiofrequency turbinate volume reduction and tongue base radiofrequency volume reduction (TBRVR) were performed, respectively, using COBLATOR®II (Arthro-Care, Austin, TX, USA) [23].

Polysomnography

All participating patients underwent full-night level I PSG at CNUH before and after surgery. Index values of PSG outcomes were classified according to the definition of the scoring manual version 2.6 of the American Academy of Sleep Medicine published in 2020. Criteria for surgical success were: 1) a decrease of more than 50% of the previous apnea-hypopnea index (AHI) and 2) AHI less than 20.

Questionnaires

Epworth Sleepiness Scale

The Epworth Sleepiness Scale (ESS) score was used to check weekly symptoms due to OSA. The ESS consisted of a total of 8 questions. For each question, a 4-point score (from 0 to 3) was obtained [24]. The total score was 24 points, with a score of 0–5, 6–10, 11–12, 13–15, and 16–24 indicating lower, higher, mild, moderate, and severe excessive daytime sleepiness, respectively.

Beck Anxiety Inventory

The Beck Anxiety Inventory (BAI) consisted of 21 items with multiple-choice to determine the severity of a patient’s anxiety [25]. In this study, the Korean version of the BAI was used [26]. For each question, patient’s answer had a 4-point score (from 0 to 3), with a total score of 0–7, 8–15, 16–25, and 26–63 indicating minimal, mild, moderate, and severe anxiety, respectively.

Beck Depression Inventory

The 21-item Beck Depression Inventory (BDI) is mainly used to measure the severity of depression [27]. The Korean version of the BDI [26] was used in this study. Each item had a 4-point score from 0 to 3, with a total score of 0–7, 8–15, 16–25, and 26–63 indicating minimal, mild, moderate, and severe depression, respectively.

Pittsburgh Sleep Quality Index

Pittsburgh Sleep Quality Index (PSQI) is a method in which patients self-evaluate their sleep quality over the past month [28]. It had seven components with a total of 19 items. The total score ranged from 0 to 21 to reflect the sleep quality and quantity, with a higher score indicating a poorer sleep quality.

Cephalometry

Cephalometric analysis was used to evaluate musculoskeletal abnormalities and soft tissue characteristics of the patient’s face. Lateral cephalometry was taken before surgery for all patients in a sitting position while holding their breath. All measurements included in the results were measured manually by one surgeon using the same landmarks. Variables included posterior airway space (PAS), distance from the mandibular plane to the hyoid bone (MP-H), length of the soft palate, thickness of the soft palate, length of the maxilla, and length of the mandible. The PAS diameter was measured from the extension line passing through the gonion and the supramental. The length of the soft palate was calculated from the posterior nasal spine to the tip of the soft palate. The maxillary length was measured as the distance from the anterior nasal spine to the posterior nasal spine. The mandibular length was calculated as the distance from the gnathion to the gonion [5,29,30].

Statistical Analysis

All statistics were performed with the Statistical Package for Social Sciences (SPSS; IBM Co., Armonk, NY, USA) version 22.0. Statistics were compared with an independent sample t-test. χ2 test was used to compare the distribution of Friedman stages according to success of the operation. When the p-value was less than 0.05, it was defined as a statistically significant case.

RESULTS

Demographics

Thirty patients (1 female and 29 males) had a mean age of 40.27 years (range, 18 to 62 years). Their mean BMI was 28.34 kg/m2. AHI was observed at 42.88 events per hour before surgery. Regarding both tonsil size, size 3 (36.7%) was the most common. Nine patients had size 1 and size 2, respectively. The Friedman palate position was position III in 19 (63.3%) patients. It was position II in the rest. Friedman stage was stage II in 17 patients, stage III in 11 patients, and stage I in two other patients. As for patients’ comorbidities, four patients had hypertension, which had the highest number of patients. Two patients were being treated for diabetes and one patient was being monitored for ischemic heart disease and arrhythmia. Only one patient had both diabetes and hypertension (Table 1). One patient was taking anxiolytics and antidepressants for major depressive disorder. One patient was taking antidepressants and atypical antipsychotic medications for insomnia.

Baseline characteristics

Surgical Method

None of the 30 patients underwent EUPF alone. Twelve (40.0%) patients underwent septoturbinoplasty with EUPF. Seven patients underwent bilateral ESS surgery, EUPF and septoturbinoplasty, and five patients underwent EUPF and turbinoplasty. Patients with tongue base obstruction confirmed through physical examination underwent TBRVR. Three of four patients who received TBRVR underwent septoturbinoplasty simultaneously (Table 2). For all patients who underwent ESS, the range of surgery was determined according to the OMU CT taken before surgery. All patients underwent bilateral surgery.

Surgical procedures combined with extended uvulopalatal flap

Comparison of Polysomnography before and after Extended Uvulopalatal Flap Surgery

For follow-up, PSG was performed at an average of 6.9 (range, 2–36 months) months after surgery (Table 3). All sleep parameters of PSG except rapid eye movement (REM) latency and hypopnea index (HI) were significantly improved after surgery. Mean AHI regardless of REM or non-rapid eye movement (NREM) or position was also significantly improved mainly due to improved apnea index (AI) rather than HI. Snoring time also showed a definite decrease from 63.63 minutes to 31.18 minutes (p = 0.022). Oxygen saturation was also improved (p < 0.001). Scores to all four scores of questionnaires (ESS, BAI, BDI, and PSQI) conducted to examine patient’s subjective symptoms were all significantly reduced.

Comparison of preoperative and postoperative polysomnographic results in 30 patients

Comparison of Preoperative Polysomnography Results between ‘Success’ and ‘Failure’ Groups

Patients were divided into ‘success’ and ‘failure’ groups according to the definition of successful operation (AHI decreased by more than 50% and AHI < 20). Ten patients were assigned into the success group based on this definition, while 20 patients were assigned into the failure group (Table 4). Preoperative PSG was compared between the success group and the failure group. Among preoperative PSG parameters, AHI (p = 0.049), AI (p = 0.027) (regardless of REM or NREM sleep), and number of awakening (p = 0.032) were significantly lower in the success group than the failure group. However, mean AHI and AI calculated according to body position (supine and non-supine) did not shown significant differences between the two groups.

Comparison of preoperative PSG results between success and failure groups

Comparison of Cephalometric Parameters and Demographic Factors between Success and Failure Groups

Cephalometric and demographic factors such as PAS diameter, MP-H distance, soft palate length, soft palate thickness, maxillary length, mandibular length, age, BMI, and Friedman stage were compared between success and failure groups. However, there were no significant differences in these factors between the two groups (Table 5).

Comparison of cephalometric parameters and demographic factors between success and failure groups

Additional Treatment after Extended Uvulopalatal Flap Surgery

If a patient had an abnormality in the PSG performed after surgery, treatment was carried out after sufficient conversation with the patient. After surgery, the mean follow-up period was 9.27 months (range, 2–35 months). In the case of residual AHI, six patients wore CPAP or auto-titrating positive airway pressure. None of them used a mandibular advancement device. A total of 12 patients received conservative treatment, of which ten patients attempted to lose weight. The remaining two patients decided to proceed with positional therapy during sleep. Of the total 30 patients, eight (26.67%) complained of postoperative complications. Five patients complained of foreign body sensation. One patient complained of difficulty in eating due to VPI. Two patients had pain at the surgical site. Complications of all eight patients improved with conservative treatment. These patients are being monitored at the outpatient clinic.

DISCUSSION

It is difficult to know the exact surgical success rate because the criteria for surgical success in OSA patients are defined differently depending on the author. The results of surgery such as surgical success rate are affected over time [31]. In the case of UPPP, which has relatively more published surgical results than EUPF, Choi et al. [32] have stated that one of the critical factors in predicting the success of UPPP is the Friedman stage. The lower the stage, the higher the success rate. According to Friedman et al. [22], when the criteria of surgical success are considered as respiratory disturbance index (RDI) when patients are classified according to the Friedman stage, the surgical success rate is the highest at 80.6% in stage I and the lowest at 8.1% in stage III. Li et al. [33] have compared UPPP results with OSA severity using AHI with Friedman stage. The overall surgical success rate was 78% which was different from the overall surgical success rate of 90% in mild OSA or 74% in severe OSA, although these differences were not statistically significant. In the anatomy-based stage, the surgical success rate decreased from 100% in stage I to 96%, 65%, and 20% in stage II, III, and IV, respectively. Also, the change in AHI showed significant correlations with Friedman tongue position and tonsil size.

On the other hand, since EUPF was introduced in 2003, few papers have announced the surgical success rate for EUPF so far. In a previous study, the success rate of EUPF was 82% when considering only the decrease in RDI regardless of Friedman stage in OSA patients [34]. To our knowledge, this is the first paper to analyze surgical results for EUPF in Korean patients. Although the surgical success rate in this study was low (10 out of 30 patients), it was found that all sleep-related factors improved after surgery. Interestingly, it was found that AI significantly improved after surgery than HI during AHI regardless of REM sleep or sleeping posture. As the arousal decreased significantly along with the overall AHI decrease while deep sleep and REM sleep increased significantly, it was found that EUPF surgery improved airway obstruction in patients, which contributed to the improvement of sleep quality. In addition, it was found that ESS and PSQI scores as subjective indicators of sleep quality improved significantly after surgery.

DISE is generally performed for OSA patients preoperatively. Multilevel surgery is then performed according to the occluded area. It is known to have a high postoperative success rate. In this study, if possible, physical examination, including a DISE test, was performed before surgery. Septoturbinoplasty and TBRVR were operated together if obstruction of the nasal cavity and hypopharynx was expected. The surgical period of patients participating in this study was when positive airway pressure (PAP) was prescribed as the primary treatment for OSA patients as it was applied to medical insurance in South Korea. We tried to include patients who failed to comply with PAP and wanted surgery on their own, patients who did not show tongue base obstruction in the preoperative Müller maneuver, and relatively young patients. Therefore, in this study, the number of patients who underwent tongue base volume reduction was small, unlike other previous studies.

Braga et al. [35] have compared results of cephalometric analysis of OSA patients by dividing them into surgical success and surgical failure groups. The criterion for surgical success was patients with postoperative AHI less than 5 with postoperative AHI decreasing by more than 50% compared to preoperatively. When the two groups were compared, there were no significant differences in results of cephalometry. Similarly, in this study, the criteria for surgical success were different (AHI < 20 events/hour and AHI decreased by more than 50% compared to that before surgery). However, there were no significant differences in cephalometric variables between the two patient groups according to the success of surgery. Some studies have shown that MP-H and PAS are related to OSA [32]. Ryan et al. [36] have defined the ‘response’ of surgery as when the postoperative AI is less than four events/hour or decreased to 60% or less compared to the preoperative AI. After UPPP surgery, responders had a statistically significantly narrower PAS (p < 0.0005) and a significantly smaller ratio of PAS to tongue length (p < 0.001).

There were no cases of complications during hospitalization after surgery. Among the eight patients who developed complications, five patients complained of foreign body sensation as the most common symptom. The other patients had pain at the surgical site and VPI. However, all resolved without additional treatment. No severe complications were found.

A limitation of this study was that the number of patients participating in the study was small. This was because among patients diagnosed with OSA, not only the number of patients eligible for surgery was small, but also the number of patients with preoperative and postoperative PSG among patients who underwent EUPF was small. Second, because this study analyzed medical records retrospectively, results of DISE were insufficient and could not be added to the analysis. Finally, when analyzing cephalometry, although the same surgeon had the same reference point and measured it using the same program, bias could still occur due to characteristics of cephalometric radiographs. This is because X-ray film is a two-dimensional image, making it difficult to confirm shadows on soft tissues.

In conclusion, this is the first study that compares and analyzes surgical success rate and treatment effect before and after surgery in Korean patients undergoing an EUPF surgery. When diagnosed through PSG, EUPF surgery changed the rate of REM sleep and made significant differences in AHI, snoring time, and minimum oxygen saturation. It also resulted in a significant change in AI along with a change in AHI regarding success of the operation. Therefore, EUPF surgery can change sleep factors and improve subjective symptoms in OSA patients. It can be considered as one of the treatment options for patients with surgical indications in the future.

Notes

Availability of Data and Material

The datasets generated or analyzed during the study are available from the corresponding author on reasonable request.

Author Contributions

Conceptualization: Jae-Yoon Kang, Yong Min Kim. Data curation: MiRa Choi, Se Yeon Im. Formal analysis: Mi-Ra Choi. Funding acquisition: Yong Min Kim. Investigation: Se Yeon Im, Han Wool John Sung. Methodology: Se Yeon Im, Yong Min Kim, Soo Kyoung Park. Project administration: Yong Min Kim. Resources: Yong Min Kim. Software: Se Yeon Im. Supervision: Yong Min Kim. Validation: Yong Min Kim. Visualization: Se Yeon Im, Jae-Yoon Kang. Writing—original draft: Jae-Yoon Kang, Yong Min Kim. Writing—review & editing: Jae-Yoon Kang, Yong Min Kim.

Conflicts of Interest

The authors have no potential conflicts of interest to disclose.

Funding Statement

This work was supported by research fund of Chungnam National University.

References

1. Jordan AS, McSharry DG, Malhotra A. Adult obstructive sleep apnoea. Lancet 2014;383:736–47.
2. Malhotra A, White DP. Obstructive sleep apnoea. Lancet 2002;360:237–45.
3. Chong KB, De Vito A, Vicini C. Drug-induced sleep endoscopy in treatment options selection. Sleep Med Clin 2019;14:33–40.
4. De Vito A, Carrasco Llatas M, Vanni A, Bosi M, Braghiroli A, Campanini A, et al. European position paper on drug-induced sedation endoscopy (DISE). Sleep Breath 2014;18:453–65.
5. Partinen M, Guilleminault C, Quera-Salva MA, Jamieson A. Obstructive sleep apnea and cephalometric roentgenograms. The role of anatomic upper airway abnormalities in the definition of abnormal breathing during sleep. Chest 1988;93:1199–205.
6. Almeida FR, Henrich N, Marra C, Lynd LD, Lowe AA, Tsuda H, et al. Patient preferences and experiences of CPAP and oral appliances for the treatment of obstructive sleep apnea: a qualitative analysis. Sleep Breath 2013;17:659–66.
7. Hedner J, Zou D. Drug therapy in obstructive sleep apnea. Sleep Med Clin 2018;13:203–17.
8. Kingshott RN, Vennelle M, Coleman EL, Engleman HM, Mackay TW, Douglas NJ. Randomized, double-blind, placebo-controlled crossover trial of modafinil in the treatment of residual excessive daytime sleepiness in the sleep apnea/hypopnea syndrome. Am J Respir Crit Care Med 2001;163:918–23.
9. Weaver TE, Mancini C, Maislin G, Cater J, Staley B, Landis JR, et al. Continuous positive airway pressure treatment of sleepy patients with milder obstructive sleep apnea: results of the CPAP Apnea Trial North American Program (CATNAP) randomized clinical trial. Am J Respir Crit Care Med 2012;186:677–83.
10. Fuchs FS, Pittarelli A, Hahn EG, Ficker JH. Adherence to continuous positive airway pressure therapy for obstructive sleep apnea: impact of patient education after a longer treatment period. Respiration 2010;80:32–7.
11. Ma Y, Yu M, Gao X. The effect of gradually increased mandibular advancement on the efficacy of an oral appliance in the treatment of obstructive sleep apnea. J Clin Sleep Med 2020;16:1369–76.
12. Pavwoski P, Shelgikar AV. Treatment options for obstructive sleep apnea. Neurol Clin Pract 2017;7:77–85.
13. Ryan CF, Love LL, Peat D, Fleetham JA, Lowe AA. Mandibular advancement oral appliance therapy for obstructive sleep apnoea: effect on awake calibre of the velopharynx. Thorax 1999;54:972–7.
14. Belkhode V, Godbole S, Nimonkar S, Nimonkar P, Pisulkar S. Comparative evaluation of the efficacy of customized maxillary oral appliance with mandibular advancement appliance as a treatment modality for moderate obstructive sleep apnea patients-protocol for a randomized controlled trial. Trials 2022;23:159.
15. Morsy NE, Farrag NS, Zaki NFW, Badawy AY, Abdelhafez SA, El-Gilany AH, et al. Obstructive sleep apnea: personal, societal, public health, and legal implications. Rev Environ Health 2019;34:153–69.
16. Fujita S, Conway W, Zorick F, Roth T. Surgical correction of anatomic azbnormalities in obstructive sleep apnea syndrome: uvulopalatopharyngoplasty. Otolaryngol Head Neck Surg 1981;89:923–34.
17. Hsu YS, Hsu WC, Ko JY, Yeh TH, Lee CH, Kang KT. Association of cumulative surgeon volume and risk of complications in adult uvulopalatopharyngoplasty: a population-based study in Taiwan. J Clin Sleep Med 2020;16:423–30.
18. Kezirian EJ, Weaver EM, Yueh B, Deyo RA, Khuri SF, Daley J, et al. Incidence of serious complications after uvulopalatopharyngoplasty. Laryngoscope 2004;114:450–3.
19. Tang JA, Salapatas AM, Bonzelaar LB, Friedman M. Long-term incidence of velopharyngeal insufficiency and other sequelae following uvulopalatopharyngoplasty. Otolaryngol Head Neck Surg 2017;156:606–10.
20. Powell N, Riley R, Guilleminault C, Troell R. A reversible uvulopalatal flap for snoring and sleep apnea syndrome. Sleep 1996;19:593–9.
21. Li HY, Li KK, Chen NH, Wang PC. Modified uvulopalatopharyngoplasty: the extended uvulopalatal flap. Am J Otolaryngol 2003;24:311–6.
22. Friedman M, Ibrahim H, Bass L. Clinical staging for sleep-disordered breathing. Otolaryngol Head Neck Surg 2002;127:13–21.
23. Cavaliere M, Mottola G, Iemma M. Monopolar and bipolar radiofrequency thermal ablation of inferior turbinates: 20-month follow-up. Otolaryngol Head Neck Surg 2007;137:256–63.
24. Johns MW. A new method for measuring daytime sleepiness: the Epworth sleepiness scale. Sleep 1991;14:540–5.
25. Beck AT, Epstein N, Brown G, Steer RA. An inventory for measuring clinical anxiety: psychometric properties. J Consult Clin Psychol 1988;56:893–7.
26. Lee K, Kim D, Cho Y. Exploratory factor analysis of the Beck anxiety inventory and the Beck Depression Inventory-II in a psychiatric outpatient population. J Korean Med Sci 2018;33e128.
27. Beck AT, Ward CH, Mendelson M, Mock J, Erbaugh J. An inventory for measuring depression. Arch Gen Psychiatry 1961;4:561–71.
28. Buysse DJ, Reynolds CF 3rd, Monk TH, Berman SR, Kupfer DJ. The Pittsburgh Sleep Quality Index: a new instrument for psychiatric practice and research. Psychiatry Res 1989;28:193–213.
29. Pepin JL, Ferretti G, Veale D, Romand P, Coulomb M, Brambilla C, et al. Somnofluoroscopy, computed tomography, and cephalometry in the assessment of the airway in obstructive sleep apnoea. Thorax 1992;47:150–6.
30. Riley R, Guilleminault C, Herran J, Powell N. Cephalometric analyses and flow-volume loops in obstructive sleep apnea patients. Sleep 1983;6:303–11.
31. Sundman J, Browaldh N, Fehrm J, Friberg D. Eight-year follow-up of modified uvulopalatopharyngoplasty in patients with obstructive sleep apnea. The Laryngoscope 2021;131:E307–13.
32. Choi JH, Cho SH, Kim SN, Suh JD, Cho JH. Predicting outcomes after uvulopalatopharyngoplasty for adult obstructive sleep apnea: a meta-analysis. Otolaryngol Head Neck Surg 2016;155:904–13.
33. Li HY, Wang PC, Lee LA, Chen NH, Fang TJ. Prediction of uvulopalatopharyngoplasty outcome: anatomy-based staging system versus severity-based staging system. Sleep 2006;29:1537–41.
34. Li HY, Chen NH, Shu YH, Wang PC. Changes in quality of life and respiratory disturbance after extended uvulopalatal flap surgery in patients with obstructive sleep apnea. Arch Otolaryngol Head Neck Surg 2004;130:195–200.
35. Braga A, Grechi TH, Eckeli A, Vieira BB, Itikawa CE, Küpper DS, et al. Predictors of uvulopalatopharyngoplasty success in the treatment of obstructive sleep apnea syndrome. Sleep Med 2013;14:1266–71.
36. Ryan CF, Dickson RI, Lowe AA, Blokmanis A, Fleetham JA. Upper airway measurements predict response to uvulopalatopharyngoplasty in obstructive sleep apnea. Laryngoscope 1990;100:248–53.

Article information Continued

Fig. 1.

Extended uvulopalatal flap surgery. A: Soft palate and uvula before surgery. B: After bilateral tonsillectomy. C: A submucosal flap of the soft palate was removed by extending the incision on the upper pole of the tonsils on both sides. D: The uvula is folded over the soft palate and fixed with sutures.

Table 1.

Baseline characteristics

Characteristics (n = 30) Value
Age (yr) 40.3 ± 13.4 (18–62)
Sex (female/male) 1/29
BMI (kg/m2) 28.3 ± 4.4 (22–40)
AHI (events/hr) 42.9 ± 27.6 (13–135.2)
Physical examination
 Tonsil size
  Size 1 9 (30.0)
  Size 2 9 (30.0)
  Size 3 11 (36.7)
  Size 4 1 (3.3)
 Friedman palate position
  Position I 0
  Position II 11 (36.7)
  Position III 19 (63.3)
  Position IV 0
 Friedman stage
  Stage I 2 (6.7)
  Stage II 17 (56.7)
  Stage III 11 (36.7)
  Stage IV 0
Comorbidity*
 HTN 4 (13.3)
 DM 2 (6.7)
 Ischemic heart disease 1 (3.3)
 Arrhythmia 1 (3.3)
 MDD 1 (3.3)
 Insomnia 1 (3.3)

Values are presented as mean ± standard deviation (range) or number (%).

*

One patient has one or more comorbidities.

BMI, body mass index; AHI, apnea-hypopnea index, HTN, hypertension; DM, diabetes mellitus; MDD, major depressive disorder.

Table 2.

Surgical procedures combined with extended uvulopalatal flap

Procedures n (%)
EUPF + turbinoplasty 5 (16.7)
EUPF + septoturbinoplasty 12 (40.0)
EUPF + TBRVR 1 (3.3)
EUPF + septoturbinoplasty + TBRVR 3 (10.0)
EUPF + endoscopic sinus surgery* 1 (3.3)
EUPF + endoscopic sinus surgery + turbinoplasty 1 (3.3)
EUPF + endoscopic sinus surgery + septoturbinoplasty 7 (23.3)
Total 30 (100)
*

All endoscopic sinus surgeries were performed bilaterally.

EUPF, extended uvulopalatal flap; TBRVR, tongue base radiofrequency volume reduction.

Table 3.

Comparison of preoperative and postoperative polysomnographic results in 30 patients

Preoperative Postoperative p-value
REM latency (min) 126.8 ± 65.6 (0–285.5) 103.2 ± 51.4 (5.5–261.5) 0.410
Stage N1 (%) 24.8 ± 16.1 (3.5–84.4) 24.8 ± 17.2 (5.3–63.7) 0.010
Stage N2 (%) 43.8 ± 13.2 (10.4–66.8) 46.7 ± 23.8 (18.3–155.5) 0.047
Stage N3 (%) 9.2 ± 8.0 (0–24.8) 12.5 ± 1.8 (0–27.5) < 0.001
Stage REM (%) 15.5 ± 8.3 (0–27.6) 18.8 ± 7.9 (0–33.5) 0.001
AHI 41.8 ± 27.7 (11.6–135.2) 31.5 ± 29.6 (2.1–107.4) < 0.001
 AI 17.6 ± 27.9 (0–130.1) 11.7 ± 21.8 (0–87.3) 0.005
 HI 24.2 ± 14.7 (0.7–64.0) 19.6 ± 17.7 (2.1–61.1) 0.631
AHI in NREM 41.6 ± 29.6 (10.2–137.8) 31.5 ± 31.6 (1.4–110.6) < 0.001
 AI in NREM 16.9 ± 29.7 (0–132.5) 10.7 ± 21.9 (0–90) 0.005
 HI in NREM 25.1 ± 13.4 (5.3–62.5) 20.3 ± 19.5 (1.4–67.0) 0.631
AHI in REM 42.9 ± 26.4 (0–88) 28.6 ± 23.4 (2.5–80.0) < 0.001
 AI in REM 18.9 ± 24.3 (0–88) 12.1 ± 17.7 (0–64.6) < 0.001
 HI in REM 24.6 ± 18.3 (0–70.3) 17.3 ± 14.4 (1.2–56.1) 0.296
Non-supine AHI 25.9 ± 28.7 (0–126.1) 15.3 ± 24.7 (0–100.4) 0.001
 Non-supine AI 10.0 ± 25.6 (0–124.1) 2.5 ± 10.0 (0–54.2) 0.019
 Non-supine HI 15.9 ± 14.3 (0–53.4) 12.8 ± 18.9 (0–57.3) 0.574
Supine AHI 44.4 ± 22.4 (16.3–114.4) 34.4 ± 27.1 (2.1–98.4) 0.002
 Supine AI 17.5 ± 25.0 (0–110.8) 12.2 ± 21.1 (0–95.7) < 0.001
 Supine HI 26.2 ± 15.2 (3.3–81.5) 20.1 ± 18.0 (0.7–366.8) 0.517
Number of awakenings 39.0 ± 20.5 (18–122) 39.6 ± 22.0 (3–104) 0.001
Nadir of SpO2 (%) 82.7 ± 8.1 (61–100) 84.6 ± 7.7 (66–95) < 0.001
Snoring time (min) 63.6 ± 55.8 (0–192.6) 31.2 ± 41.2 (0–157.6) 0.022
ESS 11.1 ± 3.9 (2–20) 8.1 ± 4.6 (1–17) 0.012
BAI 14.7 ± 11.8 (0–36) 7.8 ± 8.0 (0–50) 0.016
BDI 7.3 ± 5.0 (0–20) 5.8 ± 5.8 (0–26) < 0.001
PSQI 8.9 ± 3.3 (3–15) 6.2 ± 3.2 (1–18) 0.008

Values are presented as mean ± standard deviation (range).

REM, rapid eye movement; AHI, apnea-hypopnea index; AI, apnea index; HI, hypopnea index; NREM, non-rapid eye movement; SpO2, saturation of percutaneous oxygen; ESS, Epworth Sleepiness Scale; BAI, Beck Anxiety Inventory; BDI, Beck Depression Inventory; PSQI, Pittsburgh Sleep Quality Index.

Table 4.

Comparison of preoperative PSG results between success and failure groups

Success group* (n = 10) Failure group (n = 20) p-value
REM latency (min) 127.2 ± 59.4 (73–249.5) 126.6 ± 70.2 (0–285.5) 0.983
Stage N1 (%) 20.5 ± 6.0 (11.3–31.3) 27.2 ± 19.2 (3.5–84.4) 0.174
Stage N2 (%) 44.4 ± 7.2 (36.4–54.4) 43.5 ± 15.6 (10.4–66.8) 0.840
Stage N3 (%) 12.7 ± 6.8 (0–22.2) 8.4 ± 8.3 (0–24.8) 0.171
Stage REM (%) 18.7 ± 7.5 (5.7–27.6) 13.8 ± 8.4 (0–27) 0.135
AHI 31.0 ± 10.7 (13–44.7) 47.3 ± 32.0 (11.6–135.2) 0.049
 AI 5.6 ± 6.0 (0–16.8) 24.0 ± 32.7 (0.4–130.1) 0.027
 HI 25.4 ± 9.4 (11.9–41.4) 23.5 ± 17.0 (0.7–64.0) 0.749
AHI in NREM 30.2 ± 11.1 (10.2–46) 47.3 ± 34.3 (10.3–137.8) 0.054
 AI in NREM 5.4 ± 5.6 (0–14.2) 23.0 ± 35.3 (0–132.5) 0.047
 HI in NREM 24.8 ± 10.2 (9.2–45.3) 25.2 ± 15.1 (5.3–62.5) 0.940
AHI in REM 34.3 ± 20.1 (6.6–66.5) 47.2 ± 28.6 (0–88) 0.212
 AI in REM 7.6 ± 13.2 (0–40.7) 24.8 ± 26.9 (0–88) 0.029
 HI in REM 26.7 ± 14.8 (5.8–47.1) 23.6 ± 20.2 (0–70.3) 0.673
Non-supine AHI 16.1 ± 13.7 (0–38.4) 31.1 ± 33.3 (0–126.1) 0.099
 Non-supine AI 1.8 ± 2.4 (0–6.1) 14.3 ± 31.0 (0–124.1) 0.095
 Non-supine HI 14.3 ± 12.8 (0–32.3) 16.8 ± 15.2 (0–53.4) 0.670
Supine AHI 39.5 ± 12.2 (16.4–58.7) 46.9 ± 26.0 (16.3–114.4) 0.403
 Supine AI 9.4 ± 9.4 (0–22.8) 21.8 ± 29.6 (0.4–110.8) 0.213
 Supine HI 30.1 ± 10.8 (16.4–44.3) 24.1 ± 17.0 (3.3–81.5) 0.324
Number of awakenings 28 ± 8.9 (18–47) 44.8 ± 22.6 (23–122) 0.032
Nadir of SpO2 (%) 86.1 ± 7.6 (71–100) 80.8 ± 8.0 (61–91) 0.098
Snoring time (min) 49.3 ± 55.4 (0–147.6) 71.2 ± 56.0 (8.0–192.6) 0.325

Values are presented as mean ± standard deviation (range).

*

Surgery was defined as ‘success’ if the AHI decreased by more than 50% and the AHI did not exceed 20.

PSG, polysomnography; REM, rapid eye movement; AHI, apnea-hypopnea index; AI, apnea index; HI, hypopnea index; NREM, non-rapid eye movement; SpO2, saturation of percutaneous oxygen.

Table 5.

Comparison of cephalometric parameters and demographic factors between success and failure groups

Parameters Success group* (n = 10) Failure group (n = 20) p-value
PAS diameter (mm) 14.2 ± 3.0 (9.4–18.1) 13.6 ± 4.2 (6.8–25.7) 0.700
MP-H distance (mm) 16.9 ± 5.6 (6.2–24.2) 18.8 ± 7.7 (4.6–33.5) 0.475
Soft palate length (mm) 37.5 ± 5.5 (29.0–47.7) 40.0 ± 10.6 (20.0–64.1) 0.497
Soft palate thickness (mm) 11.6 ± 1.7 (9.5–13.9) 12.3 ± 2.5 (7.7–16.4) 0.388
Maxillary length (mm) 60.1 ± 4.6 (52.9–66.9) 60.3 ± 6.4 (49.8–73.3) 0.939
Mandibular length (mm) 86.8 ± 10.0 (29.0–47.7) 88.3 ± 9.3 (68.3–105.3) 0.677
Demographics
 Age (yr) 35.7 ± 14.2 (18–56) 42.6 ± 12.8 (18–62) 0.192
 BMI (kg/m2) 27.8 ± 3.6 (22.9–33.7) 28.6 ± 4.9 (21.6–39.7) 0.644
Friedman stage 0.438
 Stage I 0 2 (10.0)
 Stage II 7 (70.0) 10 (50.0)
 Stage III 3 (30.0) 8 (40.0)
 Stage IV 0 0

Values are presented as mean ± standard deviation (range) or number (%).

*

Surgery was defined as ‘success’ if the AHI decreased by more than 50% and the AHI did not exceed 20;

χ2 test was used to compare the distribution of Friedman stages according to the success of the surgery.

PAS, posterior airway space; MP-H, distance from the mandibular plane to the hyoid bone; BMI, body mass index.